Business Context and Reporting Period
Company: Gossamer Bio, Inc. (GOSS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing seralutinib for pulmonary hypertension (PH), including pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD). The company operates as a single segment.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Total Revenue | $9,238 | $26,193 | $21,378 |
| Net Income (Loss) | $16,900 | $(29,764) | $(74,911) |
| Operating Expenses | $35,312 | $97,133 | $96,953 |
| Research & Development | $26,412 | $69,487 | $79,616 |
| General & Administrative | $8,900 | $27,646 | $17,337 |
| Cash & Cash Equivalents | $41,148 (as of June 30, 2026) | ||
| Marketable Securities | $15,878 (as of June 30, 2026) | ||
| Total Current Liabilities | $137,783 (as of June 30, 2026) | ||
| Accumulated Deficit | $(1,468,702) (as of June 30, 2026) |
Material Changes vs. Prior Period
- Net Income vs. Loss: The company reported a net income of $16.9 million for the three months ended June 30, 2026, compared to a net loss of $38.3 million in the same period in 2025. This reversal was primarily driven by a $43.8 million gain on debt extinguishment resulting from an exchange offer completed in June 2026.
- Revenue: Revenue decreased by $2.3 million (19.6%) in the three-month period to $9.2 million, primarily due to lower research and development services and cost-sharing reimbursements from its collaborator, Chiesi. However, for the six-month period, revenue increased by $4.8 million to $26.2 million.
- Operating Expenses: R&D expenses decreased by $15.2 million in the three-month period (to $26.4 million) due to reduced clinical trial costs for seralutinib. G&A expenses increased slightly in the quarter but rose significantly by $10.3 million in the six-month period, driven by severance costs from a workforce reduction and increased stock-based compensation.
- Debt Restructuring: The company exchanged approximately 90.5% of its 2027 Convertible Senior Notes for new 2030 Notes, common stock, prefunded warrants, and purchase warrants. This resulted in a significant reduction of long-term debt and the recognition of the aforementioned gain.
- Workforce Reduction: In March 2026, the company initiated a reduction of 73 employees (approx. 46% of the workforce), recognizing $6.1 million in charges in Q1 2026.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states that conditions raise substantial doubt about the company's ability to continue as a going concern. Management believes current cash resources are sufficient only to fund operations into the first quarter of 2027.
- Collaboration Termination: In a subsequent event (July 2026), the company terminated its global collaboration agreement with Chiesi and reacquired worldwide rights to seralutinib. Chiesi paid $5 million in reimbursement, but the company now bears full development and commercialization costs and obligations.
- Regulatory Outlook: The Phase 3 PROSERA study for seralutinib in PAH missed its primary endpoint (p=0.0320 vs. threshold 0.025). Despite this, the company plans to submit a New Drug Application (NDA) to the FDA in September 2026, supported by the Phase 3 data and Phase 2 confirmatory evidence.
- Debt Covenants & Maturity: The new 2030 Notes have a "springing maturity" of March 2, 2027, if more than $4.0 million of the 2027 Notes remain outstanding. As $18.9 million of 2027 Notes remain, the 2030 Notes are classified as current liabilities. The company must maintain minimum liquidity of $40 million.
- Nasdaq Compliance: The company received notice of non-compliance with Nasdaq's minimum bid price requirement ($1.00). It has until October 5, 2026, to regain compliance, potentially via a reverse stock split (approved by shareholders in July 2026).
- Legal Proceedings: A putative class action lawsuit was filed in March 2026 alleging false/misleading statements regarding the company's business and prospects. The case is currently stayed pending the appointment of lead counsel.
Investor Verification Checklist
- Liquidity Runway: Verify the company's ability to raise capital before Q1 2027 to avoid insolvency, given the "substantial doubt" disclosure.
- Debt Maturity Risk: Confirm the status of the remaining $18.9 million in 2027 Notes and the company's plan to satisfy the March 2027 springing maturity of the 2030 Notes.
- NDA Submission: Monitor the September 2026 NDA submission for seralutinib and the FDA's acceptance for filing, especially given the missed primary endpoint in the Phase 3 trial.
- Reverse Stock Split: Track the implementation of the approved reverse stock split (1-for-10 to 1-for-150) to ensure compliance with Nasdaq listing rules.
- Post-Termination Costs: Assess the impact of the terminated Chiesi collaboration on future cash burn, as the company now assumes 100% of development and commercialization costs.
- Dilution: Review the impact of the 254 million new shares and 135 million purchase warrants issued in the debt exchange on existing shareholder value.